ASCO25 GI Malignancies: Key Updates With Dr Loaiza-Bonilla скачать в хорошем качестве

ASCO25 GI Malignancies: Key Updates With Dr Loaiza-Bonilla

0:00 Introduction to the OncoloGIST 0:21 Takeaways from ASCO 2025 0:56 LBA5 Event-free survival from the MATTERHORN trial 4:49 LBA4012 Disitamab Vedotin combination in GI cancer 9:24 LBA1 ATOMIC trial in colon cancer 14:38 Abstract 4000 CheckMate 577 Trial 21:30 Abstract 4018 in pancreatic cancer 25:00 Artificial intelligence in oncology In this video, Dr. Loaiza-Bonilla shares his expert insights on: -MATTERHORN Trial (Gastric/GEJ Adenocarcinoma): Understanding the implications of perioperative durvalumab for patient outcomes. -LBA4012 (HER2+ Gastric Cancer): The potential of disitamab vedotin, toripalimab, and chemo/trastuzumab in first-line treatment. -ATOMIC Trial (dMMR Stage III Colon Cancer): The transformative impact of atezolizumab plus FOLFOX. -CheckMate 577 (Esophageal/GEJ Cancer): Latest OS updates for adjuvant nivolumab. -DESTINY-Gastric04 (HER2+ Gastric Cancer): Solidifying the role of Trastuzumab Deruxtecan (T-DXd). -EBC-129 (Pancreatic Cancer): Promising early activity of a novel ADC in a challenging disease. -AI in Oncology Get a concise overview of how these groundbreaking trials are shaping the future of GI cancer treatment and what they mean for patients and clinicians. #ASCO2025 #GIMalignancies #Oncology #CancerResearch #GastricCancer #ColorectalCancer #PancreaticCancer #Immunotherapy #TargetedTherapy #ClinicalTrials #MedicalBreakthroughs #CancerTreatmentFor more resources and information regarding anticancer targeted therapies: http://targetedonc.com/